Enzo Biochem Stock EBITDA

ENZ Stock

USD 1.08 0.05 4.85%

Enzo Biochem fundamentals help investors to digest information that contributes to Enzo Biochem's financial success or failures. It also enables traders to predict the movement of Enzo Stock. The fundamental analysis module provides a way to measure Enzo Biochem's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Enzo Biochem stock.

		Last Reported	Projected for Next Year
	EBITDA	-8.3 M	-7.9 M

EBITDA is likely to rise to about (7.9 M) in 2024.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Enzo Biochem Company EBITDA Analysis

Enzo Biochem's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

EBITDA

Revenue

-

Basic Expenses

More About EBITDA | All Equity Analysis

Current Enzo Biochem EBITDA

(8.35 M)

Most of Enzo Biochem's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Enzo Biochem is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Enzo EBITDA Driver Correlations

Understanding the fundamental principles of building solid financial models for Enzo Biochem is extremely important. It helps to project a fair market value of Enzo Stock properly, considering its historical fundamentals such as EBITDA. Since Enzo Biochem's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Enzo Biochem's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Enzo Biochem's interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Net Receivables	Total Liab	Total Current Assets	Intangible Assets	Accounts Payable	Short Term Debt	Common Stock	Good Will	Property Plant Equipment	Short Term Investments	Current Deferred Revenue	Long Term Debt	Net Tangible Assets	Capital Surpluse	Short Long Term Debt	Long Term Debt Total	Cash And Equivalents	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.83	-0.54	-0.15	-0.18	0.23	0.9	-0.59	0.01	0.1	0.47	0.0	0.47	0.14	-0.44	0.37	0.79	0.41	-0.35	0.42	-0.3	-0.28	-0.44	0.24
Total Stockholder Equity	0.83		-0.77	-0.33	0.17	-0.34	0.87	-0.38	0.25	-0.2	0.58	-0.09	0.24	-0.14	-0.4	0.09	0.84	0.37	-0.58	0.16	-0.1	-0.08	-0.12	0.18
Net Debt	-0.54	-0.77		0.14	-0.05	0.44	-0.8	0.1	-0.02	0.49	-0.37	0.12	0.2	0.49	0.24	0.41	-0.78	-0.39	0.4	0.35	-0.5	-0.07	-0.19	-0.25
Retained Earnings	-0.15	-0.33	0.14		-0.38	0.33	-0.01	-0.33	-0.34	-0.27	-0.9	0.49	-0.41	0.38	-0.39	-0.22	-0.2	-0.42	0.16	-0.16	0.19	0.35	0.35	-0.28
Net Receivables	-0.18	0.17	-0.05	-0.38		-0.54	-0.12	0.07	0.92	0.15	0.28	-0.31	-0.21	-0.21	0.15	-0.12	-0.16	-0.42	0.12	-0.08	0.17	0.6	0.55	-0.61
Total Liab	0.23	-0.34	0.44	0.33	-0.54		0.01	-0.35	-0.36	0.53	-0.2	0.05	0.39	0.49	-0.03	0.49	-0.12	0.01	0.43	0.45	-0.31	-0.28	-0.48	-0.01
Total Current Assets	0.9	0.87	-0.8	-0.01	-0.12	0.01		-0.54	-0.01	-0.21	0.39	-0.07	0.21	-0.01	-0.48	0.01	0.9	0.42	-0.45	0.08	0.06	-0.09	-0.12	0.2
Intangible Assets	-0.59	-0.38	0.1	-0.33	0.07	-0.35	-0.54		-0.09	-0.18	0.01	-0.11	-0.24	-0.47	0.84	-0.44	-0.42	-0.09	0.14	-0.51	0.33	0.0	0.17	0.16
Accounts Payable	0.01	0.25	-0.02	-0.34	0.92	-0.36	-0.01	-0.09		0.33	0.29	-0.32	-0.09	-0.11	0.02	0.08	-0.1	-0.49	0.18	0.12	0.03	0.58	0.43	-0.71
Short Term Debt	0.1	-0.2	0.49	-0.27	0.15	0.53	-0.21	-0.18	0.33		0.18	-0.14	0.4	0.27	0.08	0.55	-0.28	-0.12	0.65	0.5	-0.34	-0.11	-0.35	-0.15
Common Stock	0.47	0.58	-0.37	-0.9	0.28	-0.2	0.39	0.01	0.29	0.18		-0.62	0.54	-0.29	0.16	0.3	0.55	0.59	-0.34	0.27	-0.18	-0.39	-0.41	0.27
Good Will	0.0	-0.09	0.12	0.49	-0.31	0.05	-0.07	-0.11	-0.32	-0.14	-0.62		-0.36	0.18	-0.24	-0.12	-0.31	-0.32	0.06	-0.11	-0.21	0.07	0.02	0.16
Property Plant Equipment	0.47	0.24	0.2	-0.41	-0.21	0.39	0.21	-0.24	-0.09	0.4	0.54	-0.36		0.56	-0.03	0.63	0.36	0.49	-0.31	0.6	-0.61	-0.52	-0.63	0.33
Short Term Investments	0.14	-0.14	0.49	0.38	-0.21	0.49	-0.01	-0.47	-0.11	0.27	-0.29	0.18	0.56		-0.31	0.33	-0.06	-0.1	-0.12	0.34	-0.53	-0.03	-0.14	-0.06
Current Deferred Revenue	-0.44	-0.4	0.24	-0.39	0.15	-0.03	-0.48	0.84	0.02	0.08	0.16	-0.24	-0.03	-0.31		-0.18	-0.45	-0.13	0.3	-0.25	0.19	0.02	0.07	-0.01
Long Term Debt	0.37	0.09	0.41	-0.22	-0.12	0.49	0.01	-0.44	0.08	0.55	0.3	-0.12	0.63	0.33	-0.18		0.04	0.07	0.04	0.99	-0.71	-0.3	-0.6	-0.09
Net Tangible Assets	0.79	0.84	-0.78	-0.2	-0.16	-0.12	0.9	-0.42	-0.1	-0.28	0.55	-0.31	0.36	-0.06	-0.45	0.04		0.69	-0.62	0.1	0.02	-0.32	-0.26	0.39
Capital Surpluse	0.41	0.37	-0.39	-0.42	-0.42	0.01	0.42	-0.09	-0.49	-0.12	0.59	-0.32	0.49	-0.1	-0.13	0.07	0.69		-0.49	0.04	-0.12	-0.79	-0.63	0.82
Short Long Term Debt	-0.35	-0.58	0.4	0.16	0.12	0.43	-0.45	0.14	0.18	0.65	-0.34	0.06	-0.31	-0.12	0.3	0.04	-0.62	-0.49		0.0	0.29	0.31	0.16	-0.38
Long Term Debt Total	0.42	0.16	0.35	-0.16	-0.08	0.45	0.08	-0.51	0.12	0.5	0.27	-0.11	0.6	0.34	-0.25	0.99	0.1	0.04	0.0		-0.7	-0.25	-0.55	-0.13
Cash And Equivalents	-0.3	-0.1	-0.5	0.19	0.17	-0.31	0.06	0.33	0.03	-0.34	-0.18	-0.21	-0.61	-0.53	0.19	-0.71	0.02	-0.12	0.29	-0.7		0.52	0.69	-0.15
Net Invested Capital	-0.28	-0.08	-0.07	0.35	0.6	-0.28	-0.09	0.0	0.58	-0.11	-0.39	0.07	-0.52	-0.03	0.02	-0.3	-0.32	-0.79	0.31	-0.25	0.52		0.92	-0.78
Net Working Capital	-0.44	-0.12	-0.19	0.35	0.55	-0.48	-0.12	0.17	0.43	-0.35	-0.41	0.02	-0.63	-0.14	0.07	-0.6	-0.26	-0.63	0.16	-0.55	0.69	0.92		-0.6
Capital Stock	0.24	0.18	-0.25	-0.28	-0.61	-0.01	0.2	0.16	-0.71	-0.15	0.27	0.16	0.33	-0.06	-0.01	-0.09	0.39	0.82	-0.38	-0.13	-0.15	-0.78	-0.6

Click cells to compare fundamentals

In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.

Competition

Predict Enzo Biochem

Ebitda Over Time

Enzo Ebitda

Ebitda

(7.93 Million)

Enzo Biochem reported EBITDA of (8.35 Million) in 2023

According to the company disclosure, Enzo Biochem reported earnings before interest,tax, depreciation and amortization of (8.35 Million). This is 100.95% lower than that of the Health Care Providers & Services sector and 102.41% lower than that of the Health Care industry. The ebitda for all United States stocks is 100.21% higher than that of the company.

Enzo EBITDA Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Enzo Biochem's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Enzo Biochem could also be used in its relative valuation, which is a method of valuing Enzo Biochem by comparing valuation metrics of similar companies.

Enzo Biochem is currently under evaluation in ebitda category among its peers.

Enzo Biochem Institutional Holders

Institutional Holdings refers to the ownership stake in Enzo Biochem that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Enzo Biochem's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Enzo Biochem's value.

		Shares
Bbr Partners, Llc	2024-09-30	100 K
Nierenberg Investment Management Co	2024-09-30	88.6 K
Northern Trust Corp	2024-09-30	67.2 K
Lazard Asset Management Llc	2024-06-30	50.5 K
T. Rowe Price Associates, Inc.	2024-06-30	44.8 K
Xtx Topco Ltd	2024-09-30	34.4 K
Citadel Advisors Llc	2024-09-30	26.6 K
Kempner Capital Management Inc	2024-09-30	25.5 K
Millennium Management Llc	2024-06-30	19.4 K
Harbert Fund Advisors Inc	2024-09-30	5.2 M
Renaissance Technologies Corp	2024-09-30	2.5 M

Enzo Fundamentals

	Return On Equity	-0.15
	Return On Asset	-0.0744
	Profit Margin	(0.82) %
	Operating Margin	(0.39) %
	Current Valuation	4.95 M
	Shares Outstanding	52.24 M
	Shares Owned By Insiders	21.57 %
	Shares Owned By Institutions	31.78 %
	Number Of Shares Shorted	432.99 K
	Price To Earning	26.60 X
	Price To Book	0.96 X
	Price To Sales	1.77 X
	Revenue	31.91 M
	Gross Profit	11.57 M
	EBITDA	(8.35 M)
	Net Income	(26.08 M)
	Cash And Equivalents	82.37 M
	Cash Per Share	0.44 X
	Total Debt	3.51 M
	Debt To Equity	0.38 %
	Current Ratio	2.21 X
	Book Value Per Share	1.07 X
	Cash Flow From Operations	(26.26 M)
	Short Ratio	3.94 X
	Earnings Per Share	(0.19) X
	Target Price	5.5
	Number Of Employees	125
	Beta	0.73
	Market Capitalization	56.42 M
	Total Asset	85.76 M
	Retained Earnings	(294.43 M)
	Working Capital	45.24 M
	Current Asset	91.4 M
	Current Liabilities	20.57 M
	Annual Yield	0.39 %
	Net Asset	85.76 M

About Enzo Biochem Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Enzo Biochem's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Enzo Biochem using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Enzo Biochem based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Additional Tools for Enzo Stock Analysis

When running Enzo Biochem's price analysis, check to measure Enzo Biochem's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Enzo Biochem is operating at the current time. Most of Enzo Biochem's value examination focuses on studying past and present price action to predict the probability of Enzo Biochem's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Enzo Biochem's price. Additionally, you may evaluate how the addition of Enzo Biochem to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC